Published den 29 januari 2019 08:29
Published den 6 december 2018 10:04
Published den 28 november 2018 15:33
Published den 4 september 2018 10:41
Published den 3 september 2018 15:55
Published den 3 augusti 2018 11:37
Published den 22 maj 2018 14:03
Published den 15 maj 2018 10:15
Published den 21 februari 2018 00:00
Published den 13 februari 2018 00:00
Published den 30 juni 2016 14:37
Published den 28 juni 2016 11:33
Published den 22 juni 2016 14:25
Published den 7 mars 2016 08:37
Published den 18 september 2015 10:08
Published den 31 mars 2015 11:40
Product news
Published den 20 februari 2017 13:27
Published den 1 mars 2016 08:22
Published den 22 januari 2016 14:53
Published den 22 oktober 2015 09:07
Campaigns and offers
Published den 20 november 2017 00:00
Published den 21 november 2016 09:03
Published den 1 november 2016 00:00
Published den 5 oktober 2016 09:32
Published den 14 september 2016 00:00
Published den 17 maj 2016 10:12
Published den 3 mars 2016 10:52

AlphaHelix MRSA platform to Finland

Published den 22 juni 2016 14:25
Press release 2016-06-22

AlphaHelix has its own platform for screening of MRSA; the most common form of antibiotic-resistant bacteria. Over the past year the company has devoted substantial resources to commercialize this platform so that the technology should be made more accessible. In this work, the liquid handling robot Rob™ is an essential ingredient.

The subsidiary Techtum Lab will in the coming week set up a system for screening of MRSA in Tampere, Finland. In the first step it is about validating the system at the customer, and by fall implementation of a full installation. The system is of the same type as those currently used by among others Karolinska University Hospitals in Solna and Huddinge, but with a greater proportion of the AlphaHelix group's own products.

The business model is the same as used in Sweden where Techtum owns the equipment and is responsible for all services. The customer pays per sample. Assuming that validation in Finland passes as intended, it will give the business revenues of 2 MSEK per year for the Group. The contract period is 3-5 years.

"We have long known that our platform for MRSA is competitive but we have not been able to simplify the concept so it is possible to sell easily. Now we have a completely separate product for which we can provide secure quotes; with the certainty that it works", Techtum CEO Håkan Evefors says in a statement.

"MRSA is a worldwide health problem. The costs for the isolation of infected patients strain all healthcare budgets in Europe. Sample costs are in itself a big problem for many caregivers. Since the development of our platform was completed, in a short time we have left several quotes including the UK and Finland. We have always wanted to develop within diagnostics. With Rob™ integrated, we can soon say that we have a completely self-diagnostic platform for MRSA and VRE", Mikael Havsjö from AlphaHelix Technologies adds.

Original press release (in Swedish) at Aktietorget
Since 1975 we have provided laboratories working with DNA, RNA and proteins with innovative instruments and consumables. Techtum is especially appreciated for skilled fast personal contact and a trusted support also after purchase.
Our goal is that You, as our customer, is offered innovative/smart/cost effective products to help you in your research or diagnostics.
Our motivation is that You should feel that we are giving you that little extra in the form of better service and support than what you can get elsewhere.
Techtum Lab AB
Västra Finnbodavägen 4B
SE-131 30 Nacka 
Phone: +46 (0)90 77 88 80
Mon-Thurs: 8:00 to 4:45 p.m.
Fri: 8:00 to 4 p.m.
Our company is credit worthy according to Bisnode's credit assessment system that is based on a number of decision rules. This credit rating is updated on a daily basis, and always shows the current rating and date.